{"id":55171,"date":"2026-01-22T20:52:29","date_gmt":"2026-01-22T12:52:29","guid":{"rendered":"https:\/\/flcube.com\/?p=55171"},"modified":"2026-01-22T20:52:30","modified_gmt":"2026-01-22T12:52:30","slug":"enhertu-wins-china-nmpa-approval-for-second-line-her2-positive-gastric-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55171","title":{"rendered":"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer"},"content":{"rendered":"\n<p><strong>AstraZeneca plc<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ:\u202fAZN<\/a>) and <strong>Daiichi Sankyo Company, Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO:\u202f4568<\/a>) announced that <strong>Enhertu (trastuzumab deruxtecan)<\/strong> has been approved by China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> as a <strong>monotherapy<\/strong> for <strong>adult patients with locally advanced or metastatic HER2\u2011positive gastric or gastroesophageal junction (GEJ) adenocarcinoma<\/strong> who have received a prior trastuzumab\u2011based regimen, moving the therapy into the <strong>second\u2011line setting<\/strong> and filling a critical clinical gap.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>AstraZeneca plc (NASDAQ:\u202fAZN) and Daiichi Sankyo (TYO:\u202f4568)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Enhertu (trastuzumab deruxtecan)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>NMPA approval (new indication)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>HER2\u2011positive gastric\/GEJ adenocarcinoma, second\u2011line post\u2011trastuzumab<\/td><\/tr><tr><td><strong>Study Foundation<\/strong><\/td><td>DESTINY\u2011Gastric04 Phase\u202fIII trial<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>22\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>Moves Enhertu from third\u2011line+ to second\u2011line setting in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-destiny-gastric04\">Clinical Evidence \u2013 DESTINY\u2011Gastric04<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Enhertu (n=196)<\/th><th>Control (Chemo) (n=195)<\/th><th>p\u2011Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Median OS<\/strong><\/td><td><strong>14.7\u202fmonths<\/strong><\/td><td><strong>11.4\u202fmonths<\/strong><\/td><td><strong>0.0044<\/strong><\/td><\/tr><tr><td><strong>Confirmed ORR<\/strong><\/td><td><strong>44.3%<\/strong><\/td><td><strong>29.1%<\/strong><\/td><td>\u2013<\/td><\/tr><tr><td><strong>Median PFS<\/strong><\/td><td><strong>6.7\u202fmonths<\/strong><\/td><td><strong>5.6\u202fmonths<\/strong><\/td><td><strong>0.0074<\/strong><\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Manageable; low ILD, no new safety signals<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Design:<\/strong> First randomized Phase\u202fIII to demonstrate survival benefit in <strong>second\u2011line HER2\u2011positive unresectable\/metastatic gastric cancer<\/strong><\/li>\n\n\n\n<li><strong>Asian Representation:<\/strong> <strong>~30% Asian patients<\/strong> enhances clinical relevance for China population<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China Gastric Cancer Market<\/th><th>HER2\u2011Positive Segment<\/th><\/tr><\/thead><tbody><tr><td><strong>New Cases (2026E)<\/strong><\/td><td>450,000<\/td><td>90,000 (20% HER2\u2011positive)<\/td><\/tr><tr><td><strong>Advanced\/Metastatic at Diagnosis<\/strong><\/td><td>135,000<\/td><td>27,000<\/td><\/tr><tr><td><strong>Second\u2011Line Eligible Post\u2011Trastuzumab<\/strong><\/td><td>\u2013<\/td><td>8,100<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Chemotherapy alone (no approved HER2\u2011targeted second\u2011line)<\/td><td><\/td><\/tr><tr><td><strong>Enhertu Peak Share<\/strong><\/td><td>\u2013<\/td><td>35%<\/td><\/tr><tr><td><strong>Annual Cost (Est.)<\/strong><\/td><td>\u2013<\/td><td>$35,000\u201140,000<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u2013<\/td><td>$113\u202fmillion (China second\u2011line)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Keytruda + chemo<\/strong> (Merck) \u2013 Approved for MSI\u2011H\/dMMR gastric cancer, <strong>not HER2\u2011positive<\/strong><\/li>\n\n\n\n<li><strong>Trastuzumab<\/strong> (Roche) \u2013 First\u2011line only; <strong>no approved HER2\u2011targeted second\u2011line therapy<\/strong> in China<\/li>\n\n\n\n<li><strong>Enhertu<\/strong> \u2013 <strong>First and only HER2\u2011directed therapy<\/strong> approved for <strong>second\u2011line HER2\u2011positive gastric cancer<\/strong> in China<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> AstraZeneca\u2019s <strong>Wuxi, China biologics facility<\/strong> (capacity 80,000\u202fL) will produce Enhertu for domestic market; <strong>GMP certification<\/strong> achieved 2025<\/li>\n\n\n\n<li><strong>Commercial Reach:<\/strong> <strong>3,500\u2011person oncology sales force<\/strong> established across China; <strong>second\u2011line gastric cancer<\/strong> expands addressable market by <strong>30%<\/strong> vs. prior third\u2011line only indication<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> Eligible for <strong>NRDL Category\u202f1 negotiation<\/strong> in 2026; <strong>priority review status<\/strong> already secured<\/li>\n\n\n\n<li><strong>Global Synergy:<\/strong> Success in China reinforces <strong>Enhertu\u2019s leadership<\/strong> in <strong>HER2\u2011positive solid tumors<\/strong>, complementing existing approvals in <strong>breast and gastric cancer<\/strong> globally<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding market penetration, revenue forecasts, and competitive dynamics for Enhertu in China. Actual results may differ due to NRDL pricing negotiations, competitive entry, and clinical adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo Company, Limited (TYO:\u202f4568) announced that Enhertu (trastuzumab deruxtecan)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,130,770,16,194,871,15,978],"class_list":["post-55171","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-astrazeneca","tag-az","tag-cancer","tag-daiichi-sankyo","tag-nasdaq-azn","tag-product-approvals","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo Company, Limited (TYO:\u202f4568) announced that Enhertu (trastuzumab deruxtecan) has been approved by China\u2019s National Medical Products Administration (NMPA) as a monotherapy for adult patients with locally advanced or metastatic HER2\u2011positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab\u2011based regimen, moving the therapy into the second\u2011line setting and filling a critical clinical gap.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55171\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo Company, Limited (TYO:\u202f4568) announced that Enhertu (trastuzumab deruxtecan) has been approved by China\u2019s National Medical Products Administration (NMPA) as a monotherapy for adult patients with locally advanced or metastatic HER2\u2011positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab\u2011based regimen, moving the therapy into the second\u2011line setting and filling a critical clinical gap.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55171\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T12:52:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T12:52:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55171#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55171\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer\",\"datePublished\":\"2026-01-22T12:52:29+00:00\",\"dateModified\":\"2026-01-22T12:52:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55171\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"AstraZeneca\",\"AZ\",\"Cancer\",\"Daiichi Sankyo\",\"NASDAQ: AZN\",\"Product approvals\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55171#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55171\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55171\",\"name\":\"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T12:52:29+00:00\",\"dateModified\":\"2026-01-22T12:52:30+00:00\",\"description\":\"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo Company, Limited (TYO:\u202f4568) announced that Enhertu (trastuzumab deruxtecan) has been approved by China\u2019s National Medical Products Administration (NMPA) as a monotherapy for adult patients with locally advanced or metastatic HER2\u2011positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab\u2011based regimen, moving the therapy into the second\u2011line setting and filling a critical clinical gap.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55171#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55171\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55171#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo Company, Limited (TYO:\u202f4568) announced that Enhertu (trastuzumab deruxtecan) has been approved by China\u2019s National Medical Products Administration (NMPA) as a monotherapy for adult patients with locally advanced or metastatic HER2\u2011positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab\u2011based regimen, moving the therapy into the second\u2011line setting and filling a critical clinical gap.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55171","og_locale":"en_US","og_type":"article","og_title":"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer","og_description":"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo Company, Limited (TYO:\u202f4568) announced that Enhertu (trastuzumab deruxtecan) has been approved by China\u2019s National Medical Products Administration (NMPA) as a monotherapy for adult patients with locally advanced or metastatic HER2\u2011positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab\u2011based regimen, moving the therapy into the second\u2011line setting and filling a critical clinical gap.","og_url":"https:\/\/flcube.com\/?p=55171","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T12:52:29+00:00","article_modified_time":"2026-01-22T12:52:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55171#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55171"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer","datePublished":"2026-01-22T12:52:29+00:00","dateModified":"2026-01-22T12:52:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55171"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","AstraZeneca","AZ","Cancer","Daiichi Sankyo","NASDAQ: AZN","Product approvals","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55171#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55171","url":"https:\/\/flcube.com\/?p=55171","name":"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T12:52:29+00:00","dateModified":"2026-01-22T12:52:30+00:00","description":"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) and Daiichi Sankyo Company, Limited (TYO:\u202f4568) announced that Enhertu (trastuzumab deruxtecan) has been approved by China\u2019s National Medical Products Administration (NMPA) as a monotherapy for adult patients with locally advanced or metastatic HER2\u2011positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab\u2011based regimen, moving the therapy into the second\u2011line setting and filling a critical clinical gap.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55171#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55171"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55171#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Enhertu Wins China NMPA Approval for Second\u2011Line HER2\u2011Positive Gastric Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55171"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55171\/revisions"}],"predecessor-version":[{"id":55173,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55171\/revisions\/55173"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}